In a move that signals growing momentum for Australia’s role in advanced therapeutics, Viral Vector Manufacturing Facility has entered into a licensing agreement with global cell and gene therapy specialist OXB, opening the door to critical viral vector technologies and strengthening the nation’s position in a rapidly expanding field.
Australia stakes a claim in global gene therapy manufacturing through new partnership
March 18, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News
